Actinium Pharmaceuticals (ATNM) Stock: Climbing On New Pivotal Data

Actinium Pharmaceuticals Inc (NYSEAMERICAN: ATNM) is headed up early on in the trading session with gains of more than 6% just after the opening bell. The gains come for good reason too.

In a press release, the company said that it presented new pivotal Phase 3 data and provided a look at the data, which proved to be positive. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

ATNM Presents New Pivotal Data

As mentioned above, Actinium Pharmaceuticals is climbing after presenting new data from an ongoing pivotal Phase 3 clinical trial. The trial, known as SIERRA, is a study of the company’s Iomab-B’s single agent in patients with active, relapsed or refractory AML, also known as Acute Myeloid Leukemia. The trial includes patients ages 55 and above.

In the release, ATNM said that the data was presented at the 2019 American Society of Clinical Oncology Annual Meeting.

In the presentation, data from the first 38, or 25% of patients in the trial were evaluated. 29 of these patients received Iomab-B. Of these 19 patients received the treatment directly and 10 patients received the treatment after conventional care failed to generate a response.

Out of 16 patients for whom data was available, the median reduction of peripheral blasts was 98% by day 3 and 100% by day 8.

Why This Is Important

AML is a difficult-to-treat cancer, and the data reported by ATNM proved to be overwhelmingly positive. After all, rapid reduction of peripheral blasts is associated with both complete response and relapse-free survival in patients with AML after receiving cytotoxic chemotherapy.

With the rapid reduction in peripheral blasts among the evaluable patient population, the treatment is showing significant signs of efficacy. Should the trial continue to produce results like this, ATNM could be on the verge of regulatory approval of a blockbuster treatment option for AML patients.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Management Commentary

Older patients with active, relapsed or refractory AML are an underserved patient population. These patients, particularly those with high blast counts as seen in the SIERRA trial, are not typically considered candidates for transplant, which is a potentially curative treatment for AML, and have a poor prognosis with other therapeutic options. Iomab-B has uniquely demonstrated an ability to effectively condition these patients for transplant with robust engraftment. We hypothesized that this successful engraftment is due to the myeloablation and anti-leukemic effect of Iomab-B, since these patients had a median of 30% bone marrow blasts prior to transplant. Therefore, we are highly encouraged to observe that Iomab-B as a single agent has a significant anti-leukemic effect and rapidly reduces peripheral blasts. – SIERRA investigator Benjamin Tomlinson, M.D.

What We’ll Be Watching For Ahead

At CNA Finance, we’ll continue to keep a close eye on ATNM. With such significant reduction in peripheral blasts, the company may be onto something big with Iomab-B, and we’re excited to follow the treatment through the late-stage development process. Nonetheless, we’ll keep a close eye on the story and bring the news to you as it breaks!

What Do You Think?

Where do you think ATNM is headed moving forward? Join the discussion in the comments below!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required

Leave a Comment